ACTOPLUS MET Drug Patent Profile

When do Actoplus Met patents expire, and what generic alternatives are available?

Actoplus Met is a drug marketed by Takeda Pharms Usa and is included in two NDAs. There are four patents protecting this drug.

This drug has forty-one patent family members in twenty-five countries.

The generic ingredient in ACTOPLUS MET is metformin hydrochloride; pioglitazone hydrochloride. There are forty-nine drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the metformin hydrochloride; pioglitazone hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Actoplus Met

Indicators of Generic Entry

Summary for ACTOPLUS MET

International Patents:	41
US Patents:	2
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ACTOPLUS MET

US Patents and Regulatory Information for ACTOPLUS MET

ACTOPLUS MET is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	ACTOPLUS MET	metformin hydrochloride; pioglitazone hydrochloride	TABLET;ORAL	021842-001	Aug 29, 2005		DISCN	Yes	No	9,320,714		Y
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-002	May 12, 2009		DISCN	Yes	No	7,959,946		Y
Takeda Pharms Usa	ACTOPLUS MET	metformin hydrochloride; pioglitazone hydrochloride	TABLET;ORAL	021842-002	Aug 29, 2005	AB	RX	Yes	Yes	9,320,714		Y
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-002	May 12, 2009		DISCN	Yes	No	7,785,627		Y
Takeda Pharms Usa	ACTOPLUS MET	metformin hydrochloride; pioglitazone hydrochloride	TABLET;ORAL	021842-001	Aug 29, 2005		DISCN	Yes	No	9,101,660		Y
Takeda Pharms Usa	ACTOPLUS MET	metformin hydrochloride; pioglitazone hydrochloride	TABLET;ORAL	021842-002	Aug 29, 2005	AB	RX	Yes	Yes	9,101,660		Y

International Patents for ACTOPLUS MET

See the table below for patents covering ACTOPLUS MET around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	240698	PROCEDIMIENTO PARA PREPARAR COMPUESTOS DE 5-(4-(2-(5-ETIL-2-PIRIDIL)-ETOXI)BENZIL)-2,4-TIAZOLIDINDIONA Y SUS SALES (PROCESS FOR THE PREPARATION OF 5-(4-(2-(5-ETHYL-2-PYRIDIL)-ETHOXY)BENZYL)-2,4-THIAZOLODINEDIONE AND THEIR SALTS)
Austria	41931
Australia	5246786
Australia	572719
Brazil	1100325
Canada	1277323	DERIVES DE THIAZOLIDINEDIONE, LEUR PRODUCTION ET LEUR EMPLOI (THIAZOLIDINEDIONE DERIVATIVES, THEIR PRODUCTION AND USE)

Supplementary Protection Certificates for ACTOPLUS MET

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1506211	PA2014026	Lithuania		PRODUCT NAME: DAPAGLIFOZINUM + METFORMINUM; REGISTRATION NO/DATE: EU/1/13/900 20140116
1532149	C300569	Netherlands		PRODUCT NAME: LINAGLIPTINE, DESGEWENST IN DE VORM VAN EEN ZOUT, IN COMBINATIE MET METFORMINEHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/12/780/001-028 20120720
0193256	SPC/GB01/016	United Kingdom		PRODUCT NAME: PIOGLITAZONE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE HYDROCHLORIDE SALT; REGISTERED: CH IKS 55 378 01 20000927; CH IKS 55 378 02 20000927; CH IKS 55 378 03 20000927; UK EU/1/00/151/001 20001011; UK EU/1/00/151/002 20001011; UK EU/1/00/151/003 20001011; UK EU/1/00/151/004 20001011; UK EU/1/00/151/005 20001011; UK EU/1/00/151/006 20001011
1412357	50/2008	Austria		PRODUCT NAME: SITAGLIPTIN, GEGEBENENFALLS IN DER FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE ALS MONOPHOSPHAT, UND METFORMIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE DES HYDROCHLORIDS; NAT. REGISTRATION NO/DATE: EU/1/08/455/001-014, EU/1/08/456/001-014, EU/1/08/457/001-014 20080716; FIRST REGISTRATION: CH 58450 01-03 20080408
0861666	SPC/GB07/009	United Kingdom		SPC/GB07/009: 20070126
1412357	132008901682802	Italy		PRODUCT NAME: SITAGLIPTIN/METFORMINA CLORIDRATO(JANUMET, VELMETIA, EFFICIB); AUTHORISATION NUMBER(S) AND DATE(S): JANUMET:EU/1/08/455/001... 014; VELMETIA:EU/1/08/456/001...014;EFFICIB: EU/1/08/457/001....014, 20080716;58450-01;58450-02; 58450-03, 20080408

Actoplus MET: Investment Scenario and Fundamentals Analysis

Last updated: February 20, 2026

What Is Actoplus MET?

Actoplus MET is a combination drug for type 2 diabetes mellitus, combining pioglitazone and metformin. It is marketed by Takeda Pharmaceuticals. The drug aims to improve glycemic control in patients inadequately managed on monotherapy, offering a simplification in treatment regimens.

Market Position and Competitiveness

Market Size and Growth

The global type 2 diabetes market was valued at approximately USD 70 billion in 2022 and is projected to reach USD 120 billion by 2030, with a compound annual growth rate (CAGR) of around 6%. Combination therapies like Actoplus MET account for roughly 20% of prescriptions, driven by the increasing prevalence of diabetes.

Key Competitors

• Glucophage XR (metformin)
• Januvia (sitagliptin)
• Trulicity (dulaglutide)
• Jardiance (empagliflozin)
• Other fixed-dose combinations (FDCs) combining metformin with sulfonylureas or other agents.

Market Differentiation

Actoplus MET’s primary differentiator is its fixed-dose combination of pioglitazone and metformin, providing convenience for patients requiring dual therapy. However, safety concerns about pioglitazone's association with edema, heart failure, and bladder cancer influence prescriber preferences.

Regulatory and Patent Landscape

Regulatory Status

Approved by the FDA in 2004, Actoplus MET is a well-established treatment; however, patent protections have been largely expired or pending patent cliffs in many key markets.

Patent Status

Takeda's patent estate for Actoplus MET has faced challenges, with some patents expiring in the U.S. around 2018. Despite patent expirations, market exclusivity persists via regulatory data protection in certain regions; this limits generic competition temporarily but heightens risk of future commoditization.

R&D and Pipeline Outlook

Innovation and New Formulations

Takeda has explored extended-release formulations and combination modifications. The pipeline includes novel agents targeting insulin sensitivity and insulin secretion. There is limited evidence of new fixed-dose combinations involving pioglitazone being developed currently, possibly due to safety concerns.

Biosimilar and Generic Threats

Generic versions of metformin are available worldwide. The absence of patents on the metformin component reduces barriers to generic entry, while pioglitazone's patent expiry increases exposure to price competition.

Financial and Investment Considerations

Aspect	Details
Revenue (2022)	Estimated at USD 300 million globally (Takeda internal estimate)
Growth Drivers	Increasing diabetic patient population, adherence to combination therapy
Risks	Safety perceptions of pioglitazone, patent expiration, regulatory scrutiny
Market Penetration	Strong in North America and Europe, emerging in Asia-Pacific
Price Dynamics	Price erosion expected post-patent expiry and increased generic competition

Key Risks and Opportunities

Risks

• Safety concerns limiting prescription volume
• Patent expirations leading to price competition
• Regulatory restrictions arising from safety signals

Opportunities

• Expansion into emerging markets
• Development of safer or improved formulations
• Broader combination indications, such as in obesity or metabolic syndrome

Valuation and Investment Outlook

While no publicly available clinical trial data for new indications modifies immediate valuation, the existing market position sustains steady revenue streams. Risks inherent to pioglitazone’s safety profile and patent expiry cast uncertain long-term prospects.

Investment in Actoplus MET exposure depends on risk appetite for patent cliffs, safety perception, and market growth in diabetes management. The combination remains relevant but faces evolving competitive and regulatory environments.

Key Takeaways

• Actoplus MET is a well-established dual therapy for type 2 diabetes, with global sales around USD 300 million in 2022.
• Patent expiration and safety concerns pose significant threats to future revenue streams.
• Market expansion, especially in emerging economies, offers growth avenues.
• Generic competition and biosimilars could accelerate price erosion without new innovations.
• Investment decisions should weigh market fundamentals, patent landscapes, and ongoing safety evaluations.

FAQs

Q1: What are the primary indications for Actoplus MET?
It is indicated for patients with type 2 diabetes inadequately controlled on metformin or pioglitazone monotherapy.

Q2: How do safety concerns impact its market viability?
Safety issues related to pioglitazone limit its use, impacting prescription volume and market share.

Q3: When will patent protections expire?
Key patents in the U.S. expired around 2018; other regions may have additional protections or data exclusivity periods.

Q4: How might generic competition affect revenues?
Increased availability of generics post-patent expiry can lead to price reductions and volume increases, reducing brand premium.

Q5: Are there ongoing efforts to develop new formulations?
Takeda has explored extended-release formulations, but no new fixed-dose combinations involving pioglitazone are currently in advanced stages.

---

References

[1] Grand View Research. (2023). Diabetes Drugs Market Size, Share & Trends Analysis Report.
[2] U.S. Food and Drug Administration. (2022). Marketed Drug Approvals and Patent Data.
[3] Takeda Pharmaceuticals. (2022). Annual Report.
[4] Statista. (2023). Global Diabetes Market Forecasts and Trends.
[5] European Medicines Agency. (2022). Product Details for Actoplus MET.